Contact Us
We’re listening! Wherever you are, our global team is here to support you. Send us a message in your language and we’ll make sure it gets to the right person.
*Please note that although we are medical professionals, we are not licensed physicians. For guidance specific to your personal health, please consult a licensed doctor or healthcare professional.
“*” indicates required fields
Where is Cingal Available?
Cingal is available in over 45 countries around the world through our trusted network of exclusive distribution partners.
In countries where Cingal is available, our exclusive distributor partners are your local resource for:
Product availability
Doctor or clinic information
Ordering and support inquiries
This ensures you receive accurate, region-specific guidance from experienced partners who understand your local healthcare landscape. Use the interactive map below to explore where Cingal is currently offered.
Use the interactive map below to explore where Cingal is currently offered
Explore Availability
Hover over any country on the map to see whether Cingal is available in that region.
Expanding Global Access
We are continuously working to bring Cingal to new markets. If Cingal is not currently available in your country, we encourage you to:
- Speak with your healthcare provider about treatment options
- Check this page periodically for updates
- Contact us to inquire about future availability in your region
Market Approvals
In the European Economic Area and other parts of the world, Cingal is indicated as a viscoelastic supplement or a replacement for synovial fluid in human knee joints. Cingal is well suited for rapid and long-term relief of the symptoms of human knee joint dysfunctions, such as osteoarthritis. The actions of Cingal are long-term relief of symptoms by lubrication and mechanical support supplemented by short-term pain relief provided by triamcinolone hexacetonide.1
In Canada, Cingal is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics (e.g. acetaminophen). Cingal includes an ancillary steroid to provide additional short-term pain relief.2
- AML 500-277/E 07/2020
- AML 500-305/B 12/2015
Cingal is not yet available in the United States, but progress is actively underway. Anika is engaged in ongoing dialogue with the FDA and is making steady progress toward an Investigational New Drug (IND) submission. This important regulatory step reflects Anika’s commitment to bringing Cingal to U.S. patients, where its proven clinical efficacy and safety profile have already earned widespread adoption internationally.
Cingal may not be available in all geographies. Product availability is subject to the regulatory clearances in individual markets. Please reach out to your local representative or Contact Us if you have questions about specific market approvals.